Experts Video Reports: Lung Cancer track

Reporting onsite from AACR 2022 in New Orleans, Nicolas Girard discusses practice changing results from the CheckMate 816 trial involving the addition of neoadjuvant nivolumab to chemotherapy for resectable (IB-IIIA) NSCLC. He further reviews the encouraging results at 2 years from CodeBreaK100 with sotorasib in pretreated patients with KRASp.G12C-mutated NSCLC.

Reporting from the ESMO Congress 2021, Robin Cornelissen discusses novel precision medicine strategies for patients with NSCLC. He explains the response results from the ZENITH20-4 cohort in first-line treatment with poziotinib for HER2 exon 20 mutated NSCLC and reviews promising results from the Atalante-1 phase III study, testing a vaccine strategy in patients with HLA-A2+ NSCLC after immunotherapy failure. Finally, he explains the outcomes from datopotamab deruxtecan in mNSCLC with actionable genomic alterations by detailing the encouraging results from the TROPION-PanTumor01 study.

Reporting from 2021 ASCO Annual Meeting, Heather Wakelee comments on promising results from IMPOWER 010 testing atezolizumab vs best standard of care after adjuvant chemotherapy for stage II NSCLC with tumour expressing PD-L1. She also reports the overall survival results and subgroup analysis from the CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS G12C mutated NSCLC, as the drug has just been approved in the US.

Reporting from ESMO Virtual Congress 2020, Noemi Reguart comments on long term follow-up results from studies testing first-line and maintenance immunotherapy in advanced NSCLC. She also discusses promising results testing a combination of ICI with chemotherapy in extensive stage SCLC, and emphasises the need for more exploration to identify which groups of patient may benefit the most.

Reporting remotely on findings presented at ASCO 2020 Virtual Meeting, Egbert Smit comments on important and potentially practice changing study results in NSCLC.

Reporting from ESMO 2019 Congress, Martin Reck comments on the results from 2 trials studying a combination of chemotherapy and immune checkpoint inhibitor in the first-line treatment of patients with extensive stage small cell lung cancer (SCLC), and a trial studying anlotinib in heavily pretreated patients with relapsed SCLC. He explains that after decades of research there are moderately positive results and more analysis is needed to identify meaningful biomarkers.

Reporting from ESMO Congress 2019, Sanjay Popat comments on results from 3 studies presented in Malignant Pleural Mesothelioma. Considering the results, he thinks that we need to better identify the patients who may benefit from checkpoint inhibitors. In the relapse setting we have modest activity of 22% overall response rate, and to improve those results we should look at checkpoint inhibitors in the front line setting.

Reporting from ELCC 2019 in Geneva, M. Pérol explains the Tumour Mutational Burden from the biomarker’s perspective, details recent assessment methods and how the test results may be useful in Non-Small Cell Lung Cancer patients to select first-line treatment.

Reporting from ELCC 2019 in Geneva, C. Lindsay comments on the results of a multicentre study which aimed to analyse circulating tumour cells in advanced NSCLC and their potential clinical role. He also showed results from a study analysing plasma ctDNA in advanced NSCLC patients with isolated CNS metastases.

Reporting from AACR 2019 in Atlanta, M. Garassino comments on two studies about the immunotherapy outcomes in NSCLC patients presenting with brain or liver metastasis, and the use of Tumour Mutational Burden as a biomarker in metastatic NSCLC patients.